{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:08:17Z","timestamp":1790204897042,"version":"4.1.0"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T00:00:00Z","timestamp":1523923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,30]]},"abstract":"<jats:p>Our trial of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate in antiretroviral therapy\u2013naive HIV-2\u2013infected individuals for 48 weeks, in a resource-limited setting, demonstrated favorable immunovirologic outcomes and was well tolerated.<\/jats:p>","DOI":"10.1093\/cid\/ciy324","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T06:57:59Z","timestamp":1523602679000},"page":"1588-1594","source":"Crossref","is-referenced-by-count":35,"title":["A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa"],"prefix":"10.1093","volume":"67","author":[{"given":"Selly","family":"Ba","sequence":"first","affiliation":[{"name":"Service des Maladies Infectieuses et Tropicales Ibrahima Diop Mar, Centre Hospitalier National Universitaire de Fann, Universite Cheikh Anta Diop de Dakar, Senegal; and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana N","family":"Raugi","sequence":"additional","affiliation":[{"name":"Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Smith","sequence":"additional","affiliation":[{"name":"Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Sall","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses et Tropicales Ibrahima Diop Mar, Centre Hospitalier National Universitaire de Fann, Universite Cheikh Anta Diop de Dakar, Senegal; and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadim","family":"Faye","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses et Tropicales Ibrahima Diop Mar, Centre Hospitalier National Universitaire de Fann, Universite Cheikh Anta Diop de Dakar, Senegal; and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E","family":"Hawes","sequence":"additional","affiliation":[{"name":"Epidemiology"},{"name":"Global Health, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Papa Salif","family":"Sow","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses et Tropicales Ibrahima Diop Mar, Centre Hospitalier National Universitaire de Fann, Universite Cheikh Anta Diop de Dakar, Senegal; and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moussa","family":"Seydi","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses et Tropicales Ibrahima Diop Mar, Centre Hospitalier National Universitaire de Fann, Universite Cheikh Anta Diop de Dakar, Senegal; and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey S","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"Medicine"},{"name":"Global Health, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"University of Washington\u2013Dakar HIV-2 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatou","family":"Traore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Pierre Sy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bintou","family":"Diaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mbaye","family":"Ndoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amadou","family":"Bale Diop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Fadam Diome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alassane","family":"Niang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Jacques Malomar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ElHadji","family":"Ibrahima Sall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ousseynou","family":"Cisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahima","family":"Tito Tamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Philippe Diatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Sambou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Bakhoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Gomis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle","family":"Benzekri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Kiviat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Masoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Coombs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,4,17]]},"reference":[{"key":"2019120223405050000_CIT0001","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1001\/jama.1993.03510170073033","article-title":"Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic [published erratum appears in JAMA 1994 Jan 19;271(3):196] [see comments]","volume":"270","author":"De Cock","year":"1993","journal-title":"JAMA"},{"key":"2019120223405050000_CIT0002","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1097\/QAD.0b013e32830edd44","article-title":"A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa","volume":"22","author":"Gottlieb","year":"2008","journal-title":"AIDS"},{"key":"2019120223405050000_CIT0003","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/cid\/ciq248","article-title":"Update on human immunodeficiency virus (HIV)-2 infection","volume":"52","author":"Campbell-Yesufu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2019120223405050000_CIT0004","doi-asserted-by":"crossref","first-page":"8979","DOI":"10.1128\/JVI.79.14.8979-8990.2005","article-title":"The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates","volume":"79","author":"Ari\u00ebn","year":"2005","journal-title":"J Virol"},{"key":"2019120223405050000_CIT0005","volume-title":"UNAIDS 2017","author":"Joint United Nations Programme on HIV\/AIDS"},{"key":"2019120223405050000_CIT0006","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/QAD.0b013e32835a11a4","article-title":"Changing HIV epidemics: what HIV-2 can teach us about ending HIV-1","volume":"27","author":"Gottlieb","year":"2013","journal-title":"AIDS"},{"key":"2019120223405050000_CIT0007","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0140-6736(94)90065-5","article-title":"Slower heterosexual spread of HIV-2 than HIV-1","volume":"343","author":"Kanki","year":"1994","journal-title":"Lancet"},{"key":"2019120223405050000_CIT0008","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/00002030-199311000-00002","article-title":"Cellular and plasma viral load in patients infected with HIV-2","volume":"7","author":"Simon","year":"1993","journal-title":"AIDS"},{"key":"2019120223405050000_CIT0009","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1126\/science.7915856","article-title":"Reduced rate of disease development after HIV-2 infection as compared to HIV-1","volume":"265","author":"Marlink","year":"1994","journal-title":"Science"},{"key":"2019120223405050000_CIT0010","first-page":"502","article-title":"The HIV infection in Newborns French Collaborative Study Group","volume":"13","year":"1994","journal-title":"Pediatr Infect Dis J"},{"key":"2019120223405050000_CIT0011","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.1994.03520060062033","article-title":"Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast","volume":"272","author":"Adjorlolo-Johnson","year":"1994","journal-title":"JAMA"},{"key":"2019120223405050000_CIT0012","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/00006454-199511000-00004","article-title":"Mother-to-child transmission of human immunodeficiency virus type 1 and type 2 and dual infection: a cohort study in Banfora, Burkina Faso","volume":"14","author":"Prazuck","year":"1995","journal-title":"Pediatr Infect Dis J"},{"key":"2019120223405050000_CIT0013","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1086\/339295","article-title":"Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa","volume":"185","author":"Gottlieb","year":"2002","journal-title":"J Infect Dis"},{"key":"2019120223405050000_CIT0014","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/sim.1342","article-title":"Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal","volume":"22","author":"Gilbert","year":"2003","journal-title":"Stat Med"},{"key":"2019120223405050000_CIT0015","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/01.aids.0000218554.59531.80","article-title":"Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission","volume":"20","author":"Gottlieb","year":"2006","journal-title":"AIDS"},{"key":"2019120223405050000_CIT0016","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1097\/QAD.0b013e328315cdbc","article-title":"Lower levels of HIV-2 than HIV-1 in the female genital tract: correlates and longitudinal assessment of viral shedding","volume":"22","author":"Hawes","year":"2008","journal-title":"AIDS"},{"key":"2019120223405050000_CIT0017","volume-title":"Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach","author":"World Health Organization","year":"2010"},{"key":"2019120223405050000_CIT0018","volume-title":"Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents","author":"US Department of Health and Human Services","year":"2015"},{"key":"2019120223405050000_CIT0019","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1097\/QAD.0b013e32830edd59","article-title":"HIV-2 infection: a call for controlled trials","volume":"22","author":"Matheron","year":"2008","journal-title":"AIDS"},{"key":"2019120223405050000_CIT0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1126\/science.2425430","article-title":"Isolation of a new human retrovirus from West African patients with AIDS","volume":"233","author":"Clavel","year":"1986","journal-title":"Science"},{"key":"2019120223405050000_CIT0021","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1056\/NEJM199512073332204","article-title":"A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection","volume":"333","author":"Markowitz","year":"1995","journal-title":"N Engl J Med"},{"key":"2019120223405050000_CIT0022","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJM199604183341602","article-title":"Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group","volume":"334","author":"Collier","year":"1996","journal-title":"N Engl J Med"},{"key":"2019120223405050000_CIT0023","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1001\/jama.1997.03540480062040","article-title":"Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel","volume":"277","author":"Carpenter","year":"1997","journal-title":"JAMA"},{"key":"2019120223405050000_CIT0024","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/00002030-199908200-00006","article-title":"Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV","volume":"13","author":"Witvrouw","year":"1999","journal-title":"AIDS"},{"key":"2019120223405050000_CIT0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/135965350400900115","article-title":"Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis","volume":"9","author":"Witvrouw","year":"2004","journal-title":"Antivir Ther"},{"key":"2019120223405050000_CIT0026","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.antiviral.2005.07.006","article-title":"Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density","volume":"68","author":"Willey","year":"2005","journal-title":"Antiviral Res"},{"key":"2019120223405050000_CIT0027","first-page":"S92","article-title":"Polymorphism of HIV-2 intregrase gene and in vitro phenotypic susceptibiltity of HIV-2 clinical isolates to intergrase inhibitors: raltegravir and evitegravir","volume":"12","author":"Roquebert","year":"2007","journal-title":"Antivir Ther"},{"key":"2019120223405050000_CIT0028","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/QAD.0b013e3282f51203","article-title":"Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients","volume":"22","author":"Damond","year":"2008","journal-title":"AIDS"},{"key":"2019120223405050000_CIT0029","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1086\/597802","article-title":"Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance","volume":"199","author":"Smith","year":"2009","journal-title":"J Infect Dis"},{"key":"2019120223405050000_CIT0030","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1097\/QAD.0b013e32834d8e52","article-title":"Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance","volume":"25","author":"Smith","year":"2011","journal-title":"AIDS"},{"key":"2019120223405050000_CIT0031","doi-asserted-by":"crossref","first-page":"e45372","DOI":"10.1371\/journal.pone.0045372","article-title":"Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens","volume":"7","author":"Smith","year":"2012","journal-title":"PLoS One"},{"key":"2019120223405050000_CIT0032","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/AAC.05313-11","article-title":"In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors","volume":"56","author":"Visseaux","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2019120223405050000_CIT0033","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1128\/AAC.00405-13","article-title":"Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy","volume":"57","author":"Raugi","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2019120223405050000_CIT0034","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/088922204322996590","article-title":"Are fusion inhibitors active against all HIV variants","volume":"20","author":"Poveda","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2019120223405050000_CIT0035","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1128\/AAC.01284-07","article-title":"In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors","volume":"52","author":"Desbois","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2019120223405050000_CIT0036","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn335","article-title":"HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro","volume":"62","author":"Roquebert","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2019120223405050000_CIT0037","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1097\/QAD.0b013e32833f9e36","article-title":"In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S\/GSK1349572","volume":"24","author":"Charpentier","year":"2010","journal-title":"AIDS"},{"key":"2019120223405050000_CIT0038","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1468-1293.2010.00889.x","article-title":"British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010","volume":"11","author":"Gilleece","year":"2010","journal-title":"HIV Med"},{"key":"2019120223405050000_CIT0039","volume-title":"Prise en charge me\u0301dicale des personnes infecte\u0301espar le VIH","author":"Yeni","year":"2010"},{"key":"2019120223405050000_CIT0040","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1186\/1471-2334-14-461","article-title":"Antiretroviral therapy response among HIV-2 infected patients: a systematic review","volume":"14","author":"Ekouevi","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2019120223405050000_CIT0041","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/QAD.0b013e3283377a06","article-title":"First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration","volume":"24","author":"Drylewicz","year":"2010","journal-title":"AIDS"},{"key":"2019120223405050000_CIT0042","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/cid\/cir123","article-title":"Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: the ACHIEV2E Collaboration Study Group","volume":"52","author":"Benard","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2019120223405050000_CIT0043","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1097\/QAD.0b013e32832949f0","article-title":"Good response to lopinavir\/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients","volume":"23","author":"B\u00e9nard","year":"2009","journal-title":"AIDS"},{"key":"2019120223405050000_CIT0044","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1097\/QAD.0b013e32834c4adb","article-title":"Mortality and immunovirological outcomes on antiretroviral therapy in HIV-1 and HIV-2-infected individuals in The Gambia","volume":"25","author":"Peterson","year":"2011","journal-title":"AIDS"},{"key":"2019120223405050000_CIT0045","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1097\/QAD.0000000000000414","article-title":"Virological and immunological outcomes of elvitegravir-based regimen in a treatment-na\u00efve HIV-2-infected patient","volume":"28","author":"Zheng","year":"2014","journal-title":"AIDS"},{"key":"2019120223405050000_CIT0046","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/QAD.0b013e3282f9b165","article-title":"Raltegravir treatment response in an HIV-2 infected patient: a case report","volume":"22","author":"Garrett","year":"2008","journal-title":"AIDS"},{"key":"2019120223405050000_CIT0047","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/cid\/civ124","article-title":"Dolutegravir in HIV-2-infected patients with resistant virus to first-line integrase inhibitors from the French Named Patient Program","volume":"60","author":"Descamps","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2019120223405050000_CIT0048","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/jac\/dkx090","article-title":"Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response","volume":"72","author":"Requena","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2019120223405050000_CIT0049","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcv.2015.01.001","article-title":"Dolutegravir for the treatment of HIV-2 infection","volume":"64","author":"Trevi\u00f1o","year":"2015","journal-title":"J Clin Virol"},{"key":"2019120223405050000_CIT0050","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/infdis\/jir698","article-title":"Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool","volume":"205","author":"Visseaux","year":"2012","journal-title":"J Infect Dis"},{"key":"2019120223405050000_CIT0051","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jcv.2012.06.024","article-title":"Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform","volume":"55","author":"Chang","year":"2012","journal-title":"J Clin Virol"},{"key":"2019120223405050000_CIT0052","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/cid\/civ572","article-title":"HIV-2EU-supporting standardized HIV-2 drug-resistance interpretation in Europe: an update","volume":"61","author":"Charpentier","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2019120223405050000_CIT0053","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1097\/QAD.0b013e328345766f","article-title":"Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate for the initial treatment of HIV infection","volume":"25","author":"Cohen","year":"2011","journal-title":"AIDS"},{"key":"2019120223405050000_CIT0054","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"379","author":"DeJesus","year":"2012","journal-title":"Lancet"},{"key":"2019120223405050000_CIT0055","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"2019120223405050000_CIT0056","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/QAI.0b013e318289545c","article-title":"A randomized double-blind comparison of coformulated elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results","volume":"63","author":"Zolopa","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019120223405050000_CIT0057","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1086\/596504","article-title":"Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resource-limited West Africa","volume":"48","author":"Gottlieb","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2019120223405050000_CIT0058","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/QAD.0000000000000244","article-title":"Genotypic resistance profiles of HIV-2-treated patients in West Africa","volume":"28","author":"Charpentier","year":"2014","journal-title":"AIDS"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/67\/10\/1588\/31191070\/ciy324.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/67\/10\/1588\/31191070\/ciy324.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T17:12:35Z","timestamp":1751562755000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/67\/10\/1588\/4972860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,17]]},"references-count":58,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,4,17]]},"published-print":{"date-parts":[[2018,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy324","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,11,15]]},"published":{"date-parts":[[2018,4,17]]}}}